Subscribe
shutterstock_1349460611_pavel_kapysh-1-1
Pavel Kapysh / Shutterstock.com
13 September 2021Big PharmaBen Wodecki

Bausch settles $300m antitrust case over diabetes drug price hikes

Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza (metformin hcl).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation
13 December 2021   Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.
Americas
Bausch Health resolves IBS patent litigation
7 May 2020   Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Americas
Bausch Health resolves IP litigation with Teva
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Generics
Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation
13 December 2021   Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.
Americas
Bausch Health resolves IBS patent litigation
7 May 2020   Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Americas
Bausch Health resolves IP litigation with Teva
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.

More on this story

Generics
Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation
13 December 2021   Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.
Americas
Bausch Health resolves IBS patent litigation
7 May 2020   Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Americas
Bausch Health resolves IP litigation with Teva
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.

More features

UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company